Dienogest in women with persistent endometriosis-related pelvic pain during norethisterone acetate treatment

Matteo Morotti; Fausta Sozzi; F. Sozzi; Valentino Remorgida; Pier Luigi Venturini; Simone Ferrero

doi:10.1016/j.ejogrb.2014.10.036

Dienogest in women with persistent endometriosis-related pelvic pain during norethisterone acetate treatment

Matteo Morotti, Fausta Sozzi, F. Sozzi, Valentino Remorgida, Pier Luigi Venturini, Simone Ferrero

European journal of obstetrics, gynecology, and reproductive biology · 2014 · vol. 183 , pp. 188–192 · doi:10.1016/j.ejogrb.2014.10.036 · PMID:25461377 · W1971584256

article OA: closed CC0 ⤵ 85 in-corpus citations

Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".

View at publisher → View on OpenAlex View on PubMed

⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This study investigated dienogest's efficacy for persistent endometriosis-related pelvic pain in women already being treated with norethisterone acetate.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

mesh:D004715mesh:D017699endometriosis

MeSH descriptors

Contraceptives, Oral Endometriosis Nandrolone Norethindrone Pelvic Pain Rectal Diseases Vaginal Diseases Adult Contraceptives, Oral Endometriosis Endometriosis Female Follow-Up Studies Humans Nandrolone Nandrolone Norethindrone Norethindrone Norethindrone Acetate Pain Measurement

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (36)

A dose‐ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis via openalex
Central changes associated with chronic pelvic pain and endometriosis via openalex
Consensus on current management of endometriosis via openalex
Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis via openalex
Dienogest improves human leucocyte antigen-DR underexpression and reduces tumour necrosis factor-α production in peritoneal fluid cells from women with endometriosis via openalex
Dienogest inhibits aromatase and cyclooxygenase-2 expression and prostaglandin E2 production in human endometriotic stromal cells in spheroid culture via openalex
Dienogest inhibits BrdU uptake with G0/G1 arrest in cultured endometriotic stromal cells via openalex
Dienogest inhibits nerve growth factor expression induced by tumor necrosis factor-α or interleukin-1β via openalex
Dienogest in the treatment of endometriosis via openalex
Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study via openalex
Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial via openalex
Dienogest reduces proliferation, aromatase expression and angiogenesis, and increases apoptosis in human endometriosis via openalex
Effect of norethindrone acetate in the treatment of symptomatic endometriosis. via openalex
Efficacy of dienogest in the treatment of symptomatic adenomyosis: a pilot study via openalex
Endometriosis: hormone regulation and clinical consequences of chemotaxis and apoptosis via openalex
Maintenance therapy with dienogest following gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain via openalex
Measuring quality of life in women with endometriosis: tests of data quality, score reliability, response rate and scaling assumptions of the Endometriosis Health Profile Questionnaire via openalex
Medical treatment for rectovaginal endometriosis: what is the evidence? via openalex
Multidetector computerized tomography enteroclysis vs. rectal water contrast transvaginal ultrasonography in determining the presence and extent of bowel endometriosis via openalex
Norethisterone acetate in the treatment of colorectal endometriosis: a pilot study via openalex
Peripheral changes in endometriosis-associated pain via openalex
Progestagens and anti-progestagens for pain associated with endometriosis via openalex
Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment via openalex
Reduction of the intraperitoneal inflammation associated with endometriosis by treatment with medroxyprogesterone acetate via openalex
Transvaginal ultrasonography with water-contrast in the rectum in the diagnosis of bowel endometriosis. via openalex
Treatment of symptomatic rectovaginal endometriosis with an estrogen–progestogen combination versus low-dose norethindrone acetate via openalex
W2112997260 via openalex
W6638359506 via openalex
W2101417341 via openalex
W2095424038 via openalex
W1966091296 via openalex
W2146098026 via openalex
W2157853773 via openalex
W2163315477 via openalex
W6607311167 via openalex
W6607907032 via openalex

Cited by (50)

Source provenance

europepmc: last seen: 2026-06-04T01:30:01.192114+00:00
openalex: last seen: 2026-06-04T00:00:01.174412+00:00
pubmed: last seen: 2026-05-13T22:18:10.358439+00:00

License: CC0 · commercial use OK

[1] A dose‐ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis via openalex

[2] Central changes associated with chronic pelvic pain and endometriosis via openalex

[3] Consensus on current management of endometriosis via openalex

[4] Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis via openalex

[5] Dienogest improves human leucocyte antigen-DR underexpression and reduces tumour necrosis factor-α production in peritoneal fluid cells from women with endometriosis via openalex

[6] Dienogest inhibits aromatase and cyclooxygenase-2 expression and prostaglandin E2 production in human endometriotic stromal cells in spheroid culture via openalex

[7] Dienogest inhibits BrdU uptake with G0/G1 arrest in cultured endometriotic stromal cells via openalex

[8] Dienogest inhibits nerve growth factor expression induced by tumor necrosis factor-α or interleukin-1β via openalex

[9] Dienogest in the treatment of endometriosis via openalex

[10] Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study via openalex

[11] Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial via openalex

[12] Dienogest reduces proliferation, aromatase expression and angiogenesis, and increases apoptosis in human endometriosis via openalex

[13] Effect of norethindrone acetate in the treatment of symptomatic endometriosis. via openalex

[14] Efficacy of dienogest in the treatment of symptomatic adenomyosis: a pilot study via openalex

[15] Endometriosis: hormone regulation and clinical consequences of chemotaxis and apoptosis via openalex

[16] Maintenance therapy with dienogest following gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain via openalex

[17] Measuring quality of life in women with endometriosis: tests of data quality, score reliability, response rate and scaling assumptions of the Endometriosis Health Profile Questionnaire via openalex

[18] Medical treatment for rectovaginal endometriosis: what is the evidence? via openalex

[19] Multidetector computerized tomography enteroclysis vs. rectal water contrast transvaginal ultrasonography in determining the presence and extent of bowel endometriosis via openalex

[20] Norethisterone acetate in the treatment of colorectal endometriosis: a pilot study via openalex

[21] Peripheral changes in endometriosis-associated pain via openalex

[22] Progestagens and anti-progestagens for pain associated with endometriosis via openalex

[23] Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment via openalex

[24] Reduction of the intraperitoneal inflammation associated with endometriosis by treatment with medroxyprogesterone acetate via openalex

[25] Transvaginal ultrasonography with water-contrast in the rectum in the diagnosis of bowel endometriosis. via openalex

[26] Treatment of symptomatic rectovaginal endometriosis with an estrogen–progestogen combination versus low-dose norethindrone acetate via openalex

[27] W2112997260 via openalex

[28] W6638359506 via openalex

[29] W2101417341 via openalex

[30] W2095424038 via openalex

[31] W1966091296 via openalex

[32] W2146098026 via openalex

[33] W2157853773 via openalex

[34] W2163315477 via openalex

[35] W6607311167 via openalex

[36] W6607907032 via openalex